MIRA INFORM REPORT
|
Report Date : |
04.10.2011 |
IDENTIFICATION DETAILS
|
Name : |
FOUR A PHARMA FOR PHARMACEUTICAL INDUSTRIES
SAE |
|
|
|
|
Registered Office : |
4 Bourj Al
Hussain Tower, Moharam Darwish Street, Faisal, Giza, Cairo |
|
|
|
|
Country : |
Egypt |
|
|
|
|
Financials (as on) : |
31.12.2010 |
|
|
|
|
Year of Establishment : |
2001 |
|
|
|
|
Com. Reg. No.: |
7840, Giza |
|
|
|
|
Legal Form : |
Egyptian Joint Stock Company |
|
|
|
|
Line of Business : |
Manufacturers of pharmaceutical preparations and medicines |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
US$ 300,000 |
|
Status : |
Satisfactory |
|
Payment
Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2011
|
Country Name |
Previous Rating (31.12.2010) |
Current Rating (31.03.2011) |
|
Egypt |
a2 |
a2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
SUMMARY
Company Name : FOUR A PHARMA FOR PHARMACEUTICAL INDUSTRIES SAE
Country of Origin : Egypt
Legal Form : Egyptian Joint Stock Company
Registration Date : 2001
Commercial Registration Number : 7840, Giza
Issued Capital : £E 5,000,000
Paid up Capital : £E 5,000,000
Total Workforce : 75
Activities : Manufacturers of pharmaceutical preparations and medicines.
Financial Condition : Fair
Payments : Nothing detrimental uncovered
Operating Trend : Steady
Recommended Credit Limit : US$ 300,000
COMPANY NAME
FOUR A PHARMA FOR
PHARMACEUTICAL INDUSTRIES SAE
company ADDRESS
Registered &
Physical Address
Building : 4 Bourj Al Hussain Tower
Street : Moharam Darwish Street
Area : Faisal, Giza
Town : Cairo
Country : Egypt
Telephone : (20-2) 37238153 / 37238154
Facsimile : (20-2) 37238152
Email : info@fourapharma.com
Premises
Subject operates
from a medium sized suite of offices that are rented and located in the Central
Business Area of Cairo.
Branch Office (s)
Location Description
·
Plot
No. 8 Factory
premises
3rd Industrial Area
6th of October City
KEY PRINCIPALS
Name Position
·
Ali
Abdul Fattah Ali Chairman
·
Mohamed
Abdul Fattah Ali Director
·
Nagwa
Saeed Mostafa Director
·
Attar
Ezzat General
Manager
·
Dr
Jamal Mostafa Research
& Development Manager
·
Dr
Tamer Mohamed Samir Technical
Manager
·
Asim
Salem Export
Manager
·
Zakareya
Sobhy Finance
Manager
LEGAL FORM & OWNERS
Date of Establishment : 2001
Legal Form :
Egyptian Joint Stock
Company
Commercial Reg. No. : 7840, Giza
Issued Capital : £E 5,000,000
Paid up Capital : £E 5,000,000
Name of
Shareholder (s)
·
Ali Abdul
Fattah Ali
·
Mohamed
Abdul Fattah Ali
·
Nagwa
Saeed Mostafa
·
Local
businessmen and private investors
OPERATIONS
Activities: Engaged in the manufacture of
pharmaceutical preparations and medicines.
Import
Countries: Europe and the
Far East.
Operating Trend: Steady
Subject has a
workforce of 75 employees.
FINANCIAL DATA
Financial
highlights provided by local sources are given below:
Currency: Egyptian
Pounds (£E)
Year
Ending 31/12/09: Year
Ending 31/12/10:
Total Sales £E 23,500,000 £E 24,200,000
Local sources
consider subject’s financial condition to be Fair.
The above financial
figures are based on estimations by our local sources.
BANKERS
·
National
Societe Generale Bank
5 Champollion Street
Cairo
Tel: (20-2) 37707777
Fax:
(20-2) 37707799
PAYMENT HISTORY
No complaints
regarding subject’s payments have been reported.
GENERAL COMMENTS
Local sources
report that payment obligations are met in a generally timely manner and the
operating history is clear. As such the company is deemed a fair trade risk and
the above credit figure is considered to be within subject’s financial means.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.49.42 |
|
UK Pound |
1 |
Rs.76.72 |
|
Euro |
1 |
Rs.65.85 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.